Navigation Links
Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
Date:6/8/2012

AMSTERDAM, June 8, 2012 /PRNewswire/ -- Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL, Amsterdam, The Netherlands) have signed a strategic alliance to advance cancer research. With a clear focus on the advantages of radiotherapy, both parties intend to collaborate more closely in the coming years to jointly develop new breakthrough solutions that combine multimodality imaging and radiotherapy.

Working in collaboration with Elekta for many years, NKI-AVL was instrumental in the development of cone beam CT (CBCT) imaging technology and its integration with the radiation therapy system. With the assistance of NKI-AVL and other clinical partners, Elekta was the first provider to commercialize CBCT with its X-ray Volume Imaging (XVI) technique. Since then, NKI-AVL has further contributed to the refinement of image guided radiation therapy with 3D and 4D imaging innovations, which facilitate dose escalation and increase delivery accuracy. Both Elekta and NKI-AVL are eager to extend their collaboration to develop image guided adaptive radiotherapy and proton software solutions, in addition to new in vivo dosimetry and breath hold techniques. The formation of the NKI-AVL strategic alliance fully supports all of these efforts.

More than 13 million new cancer cases occur globally every year, of which three million are in Europe, according to the World Health Organization. And as the population ages, the number of cancer cases is expected to rise. Through patient-focused research and development initiatives, Elekta's goal is to increase the effectiveness and accessibility of radiation therapy for these individuals.

"We are pleased Elekta has committed to investing in the relationship and in particular this Strategic Alliance by investing in NKI-AVL research projects," says Prof. Dr. Marcel Verheij, Chair of the Radiation Oncology department at NKI-AVL. "Elekta is an important provider of innovative solutions to treat cancer."

Elekta's President and CEO Tomas Puusepp recently described how patients benefit through the company's growth and research and development leadership.

"Elekta's commitment to expansion and innovation is expected to give many more patients access to world-class, affordable cancer care," he says. "Each year, we invest 8-9 percent of our net sales in research and development with the aim of improving outcomes through the best clinical solutions on the market. This is how we pioneer modern cancer care. This strategic alliance with one of Europe's leading cancer centers is another great proof point of our strategy."

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: stina.thorman@elekta.com 
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
2. Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
4. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
5. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
6. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
9. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
10. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
11. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):